Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
40 hedge funds and large institutions have $51.9M invested in Esperion Therapeutics in 2014 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 15 increasing their positions, 14 reducing their positions, and 8 closing their positions.
12% more capital inflows, than outflows
Capital inflows: $9.68M | Capital outflows: $8.62M
7% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 14
0.22% more ownership
Funds ownership: 22.06% → 22.29% (+0.22%)
9% less funds holding
Funds holding: 44 → 40 (-4)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pentwater Capital Management
Naples,
Florida
|
+$3.79M |
| 2 |
Morgan Stanley
New York
|
+$1.93M |
| 3 |
Fort Washington Investment Advisors
Cincinnati,
Ohio
|
+$910K |
| 4 |
Bank of New York Mellon
New York
|
+$602K |
| 5 |
Bridgeway Capital Management
Houston,
Texas
|
+$388K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Polar Capital
London,
United Kingdom
|
-$3.64M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.02M |
| 3 |
MCM
Mazama Capital Management
Portland,
Oregon
|
-$786K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$476K |
| 5 |
Weiss Multi-Strategy Advisers
New York
|
-$466K |
ESPR Hedge Fund Activity: Q1 2014 in Review
40 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q1 2014, worth a combined $51.9M — up 11% from $46.7M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ESPR and 5 opened new positions — a net loss of 3 holders — while 14 trimmed existing stakes and 15 added.
The largest buyer was Pentwater Capital Management, adding an estimated $3.79M. The largest seller was Polar Capital, cutting an estimated $3.64M.
- 40 institutional investors held Esperion Therapeutics (ESPR) as of Q1 2014, down from 44 in Q4 2013.
- Funds reported $51.9M of Esperion Therapeutics stock for Q1 2014, up 11% quarter-over-quarter.
- 5 funds opened new Esperion Therapeutics positions in Q1 2014 and 8 closed out, a net change of -3 holders.
- The largest Esperion Therapeutics buyer in Q1 2014 was Pentwater Capital Management, an estimated $3.79M added.
- The largest Esperion Therapeutics seller in Q1 2014 was Polar Capital, an estimated $3.64M sold.
Based on aggregated 13F filings for Q1 2014.